Latest data updates for CRISPR Gene Therapy Tracker.https://watchboard.dev/en-ushttps://watchboard.dev/crispr-gene-therapy/#digest-2026-06-15/https://watchboard.dev/crispr-gene-therapy/#digest-2026-06-15/CRISPR gene therapy significantly reduces hereditary angioedema attacks in trial patients, per MedPage Today — a new disease indication for CRISPR therapeutics.Mon, 15 Jun 2026 00:00:00 GMTbreakinghttps://watchboard.dev/crispr-gene-therapy/#digest-2026-06-05/https://watchboard.dev/crispr-gene-therapy/#digest-2026-06-05/FDA CBER issued a landmark draft guidance on June 2, 2026 enabling genome-editing gene therapy sponsors to cross-reference prior platform CMC, nonclinical, and clinical data in new regulatory submissions — the first regulatory framework explicitly designed to accelerate the CRISPR pipeline by reducing duplicative studies across programs using shared LNP or ex vivo platforms. Intellia Therapeutics announced on June 1 that lonvo-z Phase 3 HAELO data will be presented in a late-breaking oral at EAACI 2026 (Istanbul, June 13), advancing the rolling BLA for what would be the world's first approved in vivo CRISPR therapy. At the Jefferies Global Healthcare Conference (June 3–4), the CRISPR pipeline showcased its breadth: CRISPR Therapeutics presented Casgevy's 500+ patients and CTX310 cardiovascular program; Metagenomi highlighted MGX-001 hemophilia A (compact CRISPR nuclease, IND Q4 2026); Caribou Biosciences reported CB-011's 92% ORR and RMAT designation in myeloma plus CB-010 expansion into lupus nephritis. Prime Medicine confirmed PM577 Wilson disease IND filing remains on track for H1 2026, potentially marking prime editing's clinical debut.Fri, 05 Jun 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-06-04/https://watchboard.dev/crispr-gene-therapy/#digest-2026-06-04/Metagenomi Therapeutics (MGX) CEO Jian Irish, Ph.D., M.B.A., presented a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on June 4, 2026 at 7:35 a.m. Caribou Biosciences (CRBU) CEO Rachel Haurwitz, Ph.D., participated in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 2:35 p.m.Thu, 04 Jun 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-06-03/https://watchboard.dev/crispr-gene-therapy/#digest-2026-06-03/CRISPR Therapeutics CEO Presents at Jefferies and William Blair Investor Conferences — Casgevy Commercial Ramp, CTX310 Cardiovascular Phase 1, and Allogeneic CAR-T Pipeline. Prime Medicine Announces Goldman Sachs Healthcare Conference Presentation June 10 — PM577 Wilson Disease IND on Track for H1 2026 Filing; PM647 AATD IND Mid-2026.Wed, 03 Jun 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-06-02/https://watchboard.dev/crispr-gene-therapy/#digest-2026-06-02/FDA CBER Issues Landmark Draft Guidance: 'Leveraging Prior Knowledge in Gene Therapy Products Incorporating Genome Editing' — First Regulatory Framework to Accelerate CRISPR Pipeline via Platform Data Cross-Referencing.Tue, 02 Jun 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-06-01/https://watchboard.dev/crispr-gene-therapy/#digest-2026-06-01/Intellia Therapeutics to Present lonvo-z Phase 3 HAELO Data in Late-Breaking Oral at EAACI 2026, Istanbul — Rolling BLA Advances Toward First In Vivo CRISPR Therapy Approval.Mon, 01 Jun 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-05-28/https://watchboard.dev/crispr-gene-therapy/#digest-2026-05-28/May 21: Scribe Therapeutics received regulatory clearance for STX-1150 first-in-human study — the world's first CRISPR epigenetic silencer (non-cutting ELXR platform, PCSK9 target) to reach clinical stage for cardiovascular disease. May 25–26: Editas Medicine presented EDIT-401 NHP data at EAS Congress in Athens showing a single base-editing dose achieves ≥90% reductions in LDL-C, Lp(a), and ApoB simultaneously — a cardiovascular triple-target milestone for CRISPR — alongside positive FDA pre-IND feedback; Editas also priced an up to $319.4M public offering to fund first-in-human EDIT-401 studies in H2 2026. May 28: CRISPR Therapeutics, Prime Medicine, and Caribou Biosciences announced June investor conference appearances, underscoring the breadth of CRISPR programs from approved therapies (Casgevy, 500+ patients) through prime editing's first regulatory filings.Thu, 28 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-05-26/https://watchboard.dev/crispr-gene-therapy/#digest-2026-05-26/Editas Medicine Prices Up to $319.4M Public Offering to Fund EDIT-401 Clinical Development.Tue, 26 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-05-25/https://watchboard.dev/crispr-gene-therapy/#digest-2026-05-25/Editas Medicine Presents EDIT-401 NHP Data at EAS Congress: ≥90% Reductions in LDL-C, Lp(a), and ApoB in a Single Dose; Positive FDA Pre-IND Feedback.Mon, 25 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-05-21/https://watchboard.dev/crispr-gene-therapy/#digest-2026-05-21/Nature Biotechnology published parallel DNA-guided CRISPR discoveries from independent groups at University of Florida and HKUST (May 19), overturning the 14-year-old RNA-guide paradigm with potentially more stable and chemically versatile guide molecules for diagnostics and future therapies. Scribe Therapeutics released ASGCT 2026 oral data (May 18) showing its ELXR epigenetic silencer and XE editor achieved saturating in vivo liver editing in non-human primates with zero off-target effects at 10× EC90 — advancing three cardiometabolic programs toward IND. Beam Therapeutics confirmed at the RBC Capital Markets Conference (May 20) that risto-cel BLA submission remains on track for year-end 2026, with long-term BEACON biomarker data heading to EHA 2026. Casgevy commercial milestones updated: 500+ patients initiated globally, $43M Q1 2026 net revenue for CRISPR Therapeutics; Vertex pediatric sBLA filed with FDA Commissioner's National Priority Voucher.Thu, 21 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-05-20/https://watchboard.dev/crispr-gene-therapy/#digest-2026-05-20/Beam Therapeutics management presented at the 2026 RBC Capital Markets Global Healthcare Conference on May 20, 2026, providing an update on the company's base-editing pipeline.Wed, 20 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-05-19/https://watchboard.dev/crispr-gene-therapy/#digest-2026-05-19/Nature Biotechnology: Two Independent Groups Publish DNA-Guided CRISPR Systems, Overturning the RNA-Guide Paradigm Established in 2012.Tue, 19 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-05-18/https://watchboard.dev/crispr-gene-therapy/#digest-2026-05-18/Scribe Therapeutics ASGCT 2026 Data: ELXR Epigenetic Silencer and XE Editor Achieve Saturating Liver Editing With Zero Off-Target Effects in Non-Human Primates.Mon, 18 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-05-14/https://watchboard.dev/crispr-gene-therapy/#digest-2026-05-14/Intellia Therapeutics Q1 2026 results (May 11) confirm the lonvo-z rolling BLA is advancing toward a targeted H1 2027 US launch for hereditary angioedema, while the MAGNITUDE and MAGNITUDE-2 Phase 3 trials of nex-z for ATTR amyloidosis have resumed patient screening after FDA clinical holds were lifted. Beam Therapeutics Q1 2026 results (May 7) show $1.2B cash runway extended to mid-2029; the BEAM-302 AATD pivotal cohort is expected to initiate in H2 2026 at the 60 mg optimal dose, and risto-cel BLA submission is targeted year-end 2026. Econ data updated to reflect Intellia's confirmed $207M April equity offering and Beam's strengthened cash position, reinforcing the financial health of the base-editing and in vivo CRISPR pipeline leaders.Thu, 14 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-05-11/https://watchboard.dev/crispr-gene-therapy/#digest-2026-05-11/Intellia Therapeutics announced Q1 2026 financial results and clinical pipeline updates on May 11, 2026.Mon, 11 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-05-07/https://watchboard.dev/crispr-gene-therapy/#digest-2026-05-07/Beam Therapeutics reported Q1 2026 financial results and pipeline milestones on May 7, 2026, marking a pivotal period for base-editing therapeutics.Thu, 07 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-05-06/https://watchboard.dev/crispr-gene-therapy/#digest-2026-05-06/Researchers at University of Utah Health publish findings on a newly characterized CRISPR system — Cas12a2 — that operates on a fundamentally different principle from all existing CRISPR therapeutics.Wed, 06 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-05-05/https://watchboard.dev/crispr-gene-therapy/#digest-2026-05-05/Editas Medicine reports Q1 2026 financial results alongside a significant clinical pipeline update.Tue, 05 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-05-04/https://watchboard.dev/crispr-gene-therapy/#digest-2026-05-04/CRISPR Therapeutics reports Q1 2026 financial results and a comprehensive pipeline update.Mon, 04 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-05-01/https://watchboard.dev/crispr-gene-therapy/#digest-2026-05-01/Intellia Hires 43 New Employees Post-Phase 3 Win, Issues Inducement Grants for Commercial Build-Out.Fri, 01 May 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-04-29/https://watchboard.dev/crispr-gene-therapy/#digest-2026-04-29/A historic week for gene editing: Intellia Therapeutics reported the world's first positive Phase 3 results for an in vivo CRISPR drug on April 27, with lonvoguran ziclumeran (lonvo-z) achieving 87% reduction in hereditary angioedema attacks and 62% of patients completely attack-free — a milestone validating the entire in vivo CRISPR paradigm and triggering a rolling FDA BLA submission. The FDA also approved Regeneron's Otarmeni on April 23 as the world's first gene therapy for inherited hearing loss, offered free in the US. Eli Lilly committed up to $2.25 billion to Bezos-backed Profluent for AI-designed recombinase gene editing beyond CRISPR-Cas9. Intellia priced a $180M stock offering to fund commercialization. The tracker was updated with new events, map points, KPIs, economic data, and an updated in-vivo vs. ex-vivo debate resolution reflecting the Phase 3 milestone.Wed, 29 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-04-28/https://watchboard.dev/crispr-gene-therapy/#digest-2026-04-28/Eli Lilly Signs $2.25B AI-Designed Recombinase Gene Editing Deal with Bezos-Backed Profluent — Beyond CRISPR.Tue, 28 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-04-27/https://watchboard.dev/crispr-gene-therapy/#digest-2026-04-27/World First: Intellia's In Vivo CRISPR Drug Lonvo-z Meets All Phase 3 Endpoints in HAELO Trial — 87% Attack Reduction in HAE. Intellia Announces $150M+ Public Stock Offering to Fund BLA Submission and Pre-Commercial Activities for Lonvo-z.Mon, 27 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-04-23/https://watchboard.dev/crispr-gene-therapy/#digest-2026-04-23/FDA Approves Regeneron's Otarmeni — World's First Gene Therapy for Genetic Hearing Loss, Offered Free in the US.Thu, 23 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-04-21/https://watchboard.dev/crispr-gene-therapy/#digest-2026-04-21/Nature: FDA's Plausible Mechanism Pathway Could Scale Personalized CRISPR from Individual Patients to Thousands.Tue, 21 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-04-18/https://watchboard.dev/crispr-gene-therapy/#digest-2026-04-18/At the 12th annual Breakthrough Prize ceremony in Los Angeles on April 18, 2026, Stuart H.Sat, 18 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-04-17/https://watchboard.dev/crispr-gene-therapy/#digest-2026-04-17/NEJM: Editas Reni-cel (CRISPR-Cas12a) Eliminates Sickle Cell Crises in 27 of 28 Patients in RUBY Trial. PNAS: Modified CRISPR Inserts XIST Silencer into Extra Chromosome 21 in Down Syndrome Stem Cells.Fri, 17 Apr 2026 00:00:00 GMTdailyhttps://watchboard.dev/crispr-gene-therapy/#digest-2026-04-14/https://watchboard.dev/crispr-gene-therapy/#digest-2026-04-14/NIH-Funded UT Austin Team Engineers Mini-CRISPR Al3Cas12f with 90% Editing Efficiency for AAV Delivery.Tue, 14 Apr 2026 00:00:00 GMTdaily